Company

Day One Biopharmaceuticals, Inc.

Headquarters: South San Francisco, CA, United States

Employees: 55

CEO: Dr. Jeremy Bender M.B.A., Ph.D.

NASDAQ: DAWN -1.67%

Market Cap

$1.26 Billion

USD as of Jan. 1, 2025

Market Cap History

Day One Biopharmaceuticals, Inc. market capitalization over time

Evolution of Day One Biopharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Day One Biopharmaceuticals, Inc.

Detailed Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Sept. 30, 2024
Revenue TTM $102.0 M
EBITDA $-205,504,000
Gross Profit TTM $99.7 M
Profit Margin -82.68%
Operating Margin 31.61%
Quarterly Revenue Growth 1044.54%
Financial Reports & Statistics

Stocks & Indices

Day One Biopharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: DAWN wb_incandescent

Details

Headquarters:

395 Oyster Point Boulevard

Suite 217

South San Francisco, CA 94080-1930

United States

Phone: 650 484 0899